11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Brain

Volumn 131, Issue 3, 2008, Pages 665-680

  Jack Jr , Clifford R ^a,d   Lowe, Val J ^a   Senjem, Matthew L ^b   Weigand, Stephen D ^c   Kemp, Bradley J ^a   Shiung, Maria M ^a   Knopman, David S ^d   Boeve, Bradley F ^d   Klunk, William E ^e   Mathis, Chester A ^e   Petersen, Ronald C ^d  

^a Department of Diagnostic Radiology ^*  (United States)

^b Information Services   (United States)

^c Division of Biostatistics   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Hippocampus; Magnetic resonance imaging; Mild cognitive impairment; Pittsburgh Compound B

Indexed keywords

AMYLOID; CARBON 11; 2 (4' (METHYLAMINO)PHENYL) 6 HYDROXYBENZOTHIAZOLE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; AUTOPSY; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; LEARNING; MALE; MEMORY; MORPHOMETRICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PITTSBURGH COMPOUND B; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TEMPORAL CORTEX; THREE DIMENSIONAL IMAGING; BRAIN MAPPING; DIFFERENTIAL DIAGNOSIS; EVALUATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMNESIA; ANILINE COMPOUNDS; BRAIN MAPPING; CARBON RADIOISOTOPES; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 39749108812     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm336     Document Type: Article

References (88)

1. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
2. Archer H, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-7.
3. Arnold SE, Hyman BT, Flory J, Damasio AR, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 1991; 1: 103-16.
4. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000; 11: 805-21.
5. Ashburner J, Friston KJ. Unified Segmentation. Neruoimage 2005; 26: 839-851.
6. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al., Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-4. doi:10.1001/archneur.64.3.431.
7. Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001; 14: 298-309.
8. Blomquist G, Ringheim A, Extrada S, Hoglund U, Frandberg P, Nylen G. Influx and net accumulation of PIB compared with CBF in a rhesus monkey. EJNM 2005; 32: S263.
9. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000; 95: 721-5.
10. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
11. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17.
12. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron C-J. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Brain Imaging 2002; 13: 1939.
13. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, et al. Growth arrest of individual senile plques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci 2001; 21: 858-64.
14. Crystal H, Dickson D, Sliwinski M, Lipton R, Grober E, Marks-Nelson H, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993; 34: 566-73.
15. Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado MH, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subject. Alzheimer Dis Assoc Disord 2004; 18: 190-5.
16. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989; 2: 672-3.
17. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8. doi:10.1212/01.wnl.0000244749.20056.d4.
18. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-66. doi:10.1093/brain/awl178.
19. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-9.
20. Folstein MF, Folstein SE, McHugh PR. "Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
21. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007, in press.
22. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201-5.
23. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996; 119: 2001-7.
24. Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, et al. Detection of gray matter loss in mild Alzheimer's disese with voxel-based morphometry. J Neurol Neurosurg Psychiatry 2002; 73: 657-64.
25. Genovese CR, Lazar NA, Nichols TE. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002; 15: 772-86.
26. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002; 58: 1476-82.
27. Green M, Kaye JA, Ball MJ. The Oregon Brain Aging Study. Neurology 2000; 54: 105-13.
28. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2001; 1-568.
29. Hulette CM, Welsh-Bohmer KA. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57: 1168-74.
30. Hyman B, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993; 52: 594-600.
31. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander GE, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. JMRI 2007, in press.
32. Jack CR Jr, Petersen RC, O'Brien PC. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992; 42: 183-8.
33. Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397-403.
34. Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. The rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998; 51: 993-9.
35. Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-94.
36. Jack CR Jr, Shiung MM, Weignad SD, O'Brien PC, Gunter JL, Boever BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65: 1227-31.
37. Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements for MR images in young adults. Radiology 1989; 172: 549-54.
38. Jack CR Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750-7.
39. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138-441.
40. Kaye JA, Swihart T, Howieson D, Dame A. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48: 1297-04.
41. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80. doi:10.1212/01.wnl.0000240117.55680.0a.
42. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-6. doi:10.1212/01.wnl.0000260969.94695.56.
43. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002; 58: 1188-96.
44. Kinniany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993; 50: 949-54.
45. Klunk WE, Engler H, Nordberg A, Wang Y, G B, P HD, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
46. Knopman DS, Parisi JE, Salviati A. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62: 1087-95.
47. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status: correlations with standardized psychometric testing. Arch Neurol 1991; 48: 725-8.
48. Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hanninen T, et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 1998; 19: 23-31.
49. Lopresti BJ, Klunk WE, CMathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-72.
50. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
51. McCullagh P. Regression models for ordinal data. J R Stat S Ser B (Methodol) 1980; 42: 109-42.
52. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
53. Meltzer C, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999; 40: 2053-65.
54. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52. doi:10.1212/01.wnl.0000228230.26044.a4.
55. Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's Disease. J Mol Neurosci 2001; 17: 101-18.
56. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-14.
57. Nichols TE, Brett M, Andersson JLR, Wager T, Poline J-B. Valid conjunction inference with the minimum statistic. Neuroimage 2005; 25: 653-60.
58. O'Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995; 45: 17-23.
59. Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. The Neurologist 1995; 1: 326-344.
60. Petersen RC, Doody RS, Kurz A, Hohs R, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
61. Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT. Mayo Clinic Alzheimer's Disease Patient Registry. Aging 1990; 2: 408-415.
62. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory impaired individuals. JAMA 1995; 273: 1274-78.
63. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-44.
64. Price JC, Klunk WE, Lopristi BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47.
65. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
66. Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12. doi:10.1212/01.wnl.0000259035.98480. ed.
67. Rey A.2 L'examen clinique en psychologie. Paris: Presses Universitaires de Frances; 1964; 1-221.
68. Riley KP, Snowdon DA, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findigns from the Nun Study. Ann Neurol 2002; 51: 567-77.
69. Rombouts SA, Barkhof F, Witter MP, Scheltens P. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett 2000; 285: 231-3.
70. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging {beta}-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25. doi:10.1212/01.wnl.0000261919.22630.ea.
71. Schmitt FA, Davis DG, Wekstein D. "Preclinical" AD revisted: neuropathology of cognitively normal older adults. Neurology 2000; 55: 370-6.
72. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage 2005; 26: 600-8.
73. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003; 61: 487-92.
74. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and Tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-63.
75. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease, The Nun Study. JAMA 1997; 277: 813-7.
76. Sun FT, Schriber RA, Greenia JM, He J, Gitcho A, Jagust WJ. Automated templeate-based PET region of interest analyses in the aging brain. Neuroimage 2007; 34: 608-17.
77. Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, et al. Comparison of Short Test of Mental Status and Mini Mental State Examination in mild cognitive impairment. Arch Neurol 2003; 60: 1777-81.
78. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80.
79. Thal DR, Rub U, Orantes M, Braak H. Phases of Ab-deposition in the human brain and its relevance for the development of AS. Neurology 2002; 58: 1791-800.
80. Troncoso JC, Martin LJ, Del Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996; 17: 365-71.
81. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
82. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disese beta=amyloid with (11C)SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-95.
83. Visser PJ, Scheltens P, Verhey FRJ, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999; 246: 477-85.
84. Wechsler D. Wechsler Memory Scale-Revised. New York, NY: Psychological Corp, Harcourt Brace Janvanovich, Inc.; 1987.
85. White L, Small BJ, Petrovitch H, Ross GW, Masaki K, Abbott RD, et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatr Neurol 2005; 18: 224-7.
86. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2007a; in press.
87. Whitwell JL, Weigand SD, Shiung MM, F BB, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007b; 130: 708-19.
88. Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol 2005; 57: 896-903.